Specimen Collection and Transport Workflow Evaluations for CLIA-waived Molecular Testing

Respiratory Tract Infections Clinical Trial

Official title:

Specimen Collection and Transport Workflow Evaluations for CLIA-waived Molecular Testing

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03299283
• Other study ID #: 804 Pilot
• Status: Enrolling by invitation
• Start date: October 5, 2017
• Est. completion date: December 30, 2019

Study information

• Verified date: January 2019
• Source: BioFire Diagnostics, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is two-fold. In the first phase, the goal is to characterize the stability of respiratory (nasal swab, nasopharyngeal swab, and throat swab; NS, NPS, TS) and stool (raw stool and rectal swab) specimens collected using various standard, medically established procedures with and without transport media and tested at various time points and under different temperature conditions, and also to look at variation between repeat sampling events. The intention is for these data to support decisions made by BioFire regarding the appropriate specimen type and handling guidelines for future tests. In the second phase of the study, collection and transport conditions identified in Phase 1 will be used to collect specimens for pilot performance evaluations of a new molecular diagnostic test.

Description:

This evaluation will be initiated at several sites in the US. In the first phase of the study, multiple specimens will be collected from each subject and tested using various pre-analytical techniques. Current BioFire FilmArray test panels will be used to assay each specimen and evaluate the multiple variables: repeat sampling, native specimen stability, or other post-collection variables. In the second phase of the study only two specimens will be collected from each subject: one for testing with the new test (using handling procedures identified in Phase 1) and another for testing with the reference method. Up to 2,000 subjects will be enrolled across all sites in each phase (up to 4,000 subjects total). Enrollment is expected to last approximately 18 months to cover both phases of the study. All specimens and subject data will be de-identified and coded. Prior to study initiation, each participating site will have the necessary Institutional Review Board (IRB) reviews. Specimens in both phases will be tested at the study site using various BioFire test platforms and cartridges.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 4000
• Est. completion date: December 30, 2019
• Est. primary completion date: October 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue. OR Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days

• If age 18 or over, subject provides written informed consent

• If under the age of 18, parental permission and assent (as appropriate) is obtained

• Subject is willing and able to provide at least two (up to three) specimens: any combination of NS, NPS, or TS OR rectal swab or stool

Exclusion Criteria:

• Subject is unable to provide consent or parental permission and assent (as appropriate) cannot be obtained

• Subject is unable or unwilling to provide two specimens

• Subject's health care provider determines that specimen collection represents an unacceptable risk

Related Conditions & MeSH terms

• Communicable Diseases
• Gastrointestinal Infection
• Infection
• Respiratory Tract Infections

Intervention

Diagnostic Test:
• BioFire test platform
Analysis of analyte stability under various conditions as measured by BioFire test platforms

Locations

Country	Name	City	State
United States	Washington University	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
BioFire Diagnostics, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Analyte stability (as measured by nucleic acid detection)	Sensitivity (or positive percent agreement) and specificity (or negative percent agreement) of the assays comprising the FilmArray Panel with respect to reference methods will investigate analyte stability for the various pre-analytical steps. Analyte stability will be measured by assessing nucleic acid level using real-time PCR.	Through completion of Phase 1 (approximartely 9 months)
Secondary	Device performance relative to reference methods	Sensitivity (or positive percent agreement) and specificity (or negative percent agreement) of the assays comprising the FilmArray Panel with respect to reference methods will determine device performance relative to reference method(s) i.e. if an anlyte is detected (or not) by each method (presence or absence)	Through completion of Phase 2 (approximately 9 months)